stockrow
Friday 6 November 2026
Export CRDL’s income statement to Excel — free account
Cardiol Therapeutics Inc.
CRDL Healthcare Drug Manufacturers Specialty & Generic
- EPS
- +42.9%
- Free cash flow
- +10.6%
- Total debt
- −38.8%
Quarter to June 2026, against a year earlier
0.98
0.05
+5.38%
Follow CRDL
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | — | — | — | — | — | — | 1 | 1 | 38 | +462.5% | |
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | (1) | (12) | (11) | (16) | (25) | (24) | (21) | (27) | (24) | (22) | +43.7% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | (40,197.77) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (12) | (11) | (16) | (25) | (24) | (21) | (27) | (24) | (24) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (0.06) | (0.76) | (0.41) | (0.54) | (0.58) | (0.38) | (0.33) | (0.37) | (0.28) | (0.25) | +22.3% | ||||||
| Cash flow | — | (0.04) | (0.52) | (0.34) | (0.24) | (0.43) | (0.33) | (0.29) | (0.26) | (0.20) | (0.15) | +20.4% | ||||||
| Capex | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | (0.04) | (0.52) | (0.34) | (0.24) | (0.43) | (0.34) | (0.29) | (0.26) | (0.20) | (0.15) | +20.4% | ||||||
| Book value | — | 0.10 | 1.07 | 0.44 | 0.35 | 1.41 | 0.64 | 0.32 | 0.25 | 0.15 | 0.15 | +5.1% | ||||||
| Shares, m | — | 23 | 15 | 26 | 30 | 43 | 63 | 64 | 72 | 87 | 99 | +18.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | |||||
| P/S | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | ||||||
| P/B | — | — | — | — | — | 1.75 | — | — | — | — | 6.16 | — | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | — | — | — | — | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | (1.62) | — | — | — | — | (5.11) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | (1) | (8) | (9) | (7) | (19) | (21) | (19) | (18) | (17) | (17) | +42.0% | |||||
| Capex | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (3.5%) | ||||||
| Free cash flow | — | (1) | (8) | (9) | (7) | (19) | (21) | (19) | (18) | (17) | (17) | +42.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 2 | 16 | 11 | 10 | 60 | 40 | 21 | 18 | 13 | 17 | +27.3% | |||||
| Net debt | — | (2) | (12) | (5) | (11) | (67) | (46) | (26) | (22) | (15) | (19) | +30.9% | ||||||
| Shareholders’ equity | — | 2 | 16 | 11 | 10 | 61 | 40 | 21 | 18 | 13 | 17 | +24.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | (12.82) | (128.77) | (70.00) | (133.00) | (61.10) | (40.38) | (55.64) | (106.13) | (120.54) | (124.40) | (107.7) pt | |||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | (14.24) | (125.25) | (76.10) | (149.55) | (70.83) | (47.12) | (68.23) | (137.37) | (156.96) | (171.13) | (142.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 11 | 17 | 17 | 18 | 18 | — | +13.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2021 · latest quarter Jun 2021
Cardiol Therapeutics Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics SA | $209.4M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| GLAS Glass House Brands Inc. | $172.7M | — (loss-making) | — (loss-making) | −1.24% (below 0%: shrinking) | n/m | −123.36% (below 0%: shrinking) | 33.54% | (6.37%) | Compare |
| OGI Organigram Global Inc. | $131.1M | 2.0× | 1.6× | +49.28% (above 0%: growing) | n/m | −192.32% (below 0%: shrinking) | 39.16% | 5.04% | Compare |
| BGM BGM Group Ltd. | $125.7M | 148× | 44.9× | −2.59% (below 0%: shrinking) | −85.71% (below 0%: shrinking) | +3.00% (above 0%: growing) | 7.12% | 0.00% | Compare |
| DERM Journey Medical Corporation | $121.4M | — (loss-making) | — (loss-making) | +23.33% (above 0%: growing) | n/m | −84.08% (below 0%: shrinking) | 66.81% | 2.46% | Compare |
| AKBA Akebia Therapeutics, Inc. | $117.9M | — (loss-making) | — (loss-making) | −37.20% (below 0%: shrinking) | n/m | −94.20% (below 0%: shrinking) | 82.76% | (31.06%) | Compare |
| CRDL Cardiol Therapeutics Inc. | $111.8M | — (loss-making) | — (loss-making) | — | n/m | +10.61% (above 0%: growing) | 0.00% | 0.00% | |
| ORGO Organogenesis | $108.1M | — (loss-making) | — (loss-making) | −69.87% (below 0%: shrinking) | n/m | −2,048.82% (below 0%: shrinking) | 51.83% | (64.87%) | Compare |
| CPIX Cumberland Pharmaceuticals Inc. | $75.1M | — (loss-making) | — (loss-making) | −98.46% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| Median of peers | $123.5M | — | — | −1.91% | — | −89.14% | 59.32% | (18.71%) |